专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20040258699A1 Immunotherapeutics for biodefense 审中-公开
标题翻译：免疫治疗用于生物防治
公开(公告)号：US20040258699A1
公开(公告)日：2004-12-23
申请号：US10452593
申请日：2003-06-02
发明人： Katherine S. Bowdish , Shana Frederickson , Martha A. Wild , Toshiaki Maruyama , Mary Jean Nolan
IPC分类号： A61K039/40 , A61K039/00 , A61K039/38
CPC分类号： C07K16/08 , A61K2039/505 , C07K16/1081 , C07K16/1278 , C07K2317/21 , C07K2317/55 , C12N15/1034
摘要： Human neutralizing antibodies (full-length or functional fragments) are useful as anti-toxins or anti-infectives with respect to infective agents such as, for example, anthrax, botulinum, smallpox, Venezuelan equine encephalomyelitis virus (VEEV), West Nile virus (WNV) and the like.
摘要翻译：人中和抗体（全长或功能片段）可用作抗感染剂或抗感染药物，例如炭疽，肉毒杆菌，天花，委内瑞兰马脑脊髓炎病毒（VEEV），西尼罗病毒 WNV）等。

2. 发明申请

US20040247605A1 Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines 审中-公开
标题翻译：墙壁磷酸作为抗葡萄球菌治疗和疫苗的靶标
公开(公告)号：US20040247605A1
公开(公告)日：2004-12-09
申请号：US10724194
申请日：2003-12-01
发明人： John Fitzgerald Kokai-Kun , Andreas Peschel , Christopher Weidenmaier , Sascha A. Kristian
IPC分类号： A61K039/00 , A61K039/38
CPC分类号： A61K39/085 , A61K38/164 , A61K38/4886 , A61K39/395 , A61K2039/505 , C07K16/1271 , C07K2317/24 , C12Y304/24075 , A61K2300/00
摘要： This invention provides vaccines comprising staphylococcal wall teichoic acid (WTA); vaccines comprising antibodies that specifically bind WTA; staphylococcal organisms deficient in WTA; and methods of treating patients suspected of having a staphylococcal infection.
摘要翻译：本发明提供包含葡萄球菌壁磷壁酸（WTA）的疫苗; 包含特异性结合WTA的抗体的疫苗; 葡萄球菌生物缺乏WTA; 以及治疗疑似患有葡萄球菌感染的患者的方法。

3. 发明申请

US20040241689A1 Antigens of and antibodies to translocated molecules of microorganisms and uses thereof 审中-公开
标题翻译：易位微生物分子的抗原和抗体及其用途
公开(公告)号：US20040241689A1
公开(公告)日：2004-12-02
申请号：US10485002
申请日：2004-06-28
发明人： Joel B. Baseman , Thirumalai R. Kannan , Rene Alvarez
IPC分类号： C12Q001/68 , A61K039/00 , A61K039/38
CPC分类号： C12Y102/01051 , A61K38/00 , C07K14/47 , C12N9/0008 , C12Y102/05001
摘要： This application describes intracellular, cytoplasmic molecules that are translocated to the surface of a microorganism and participate in binding the microorganism to the surface of a host cell. Examples of such translocated molecules include glycerahdehyde 3-phosphate dehydrogenase, pyruvate dehydrogenase, and elongation factor-Tu. Regions of translocated molecules important for binding, as well as molecules which disrupt binding, are described. Antibodies directed to translocated molecules are also described.
摘要翻译：本申请描述了易位于微生物表面并参与将微生物结合到宿主细胞表面的细胞内的细胞质分子。这种易位分子的实例包括甘油醛3-磷酸脱氢酶，丙酮酸脱氢酶和延伸因子-Tu。描述了对于结合重要的易位分子的区域以及破坏结合的分子。还描述了针对易位分子的抗体。

4. 发明申请

US20040219159A1 Methods and compositions for therapeutic intervention in infectious disease 审中-公开
标题翻译：传染病治疗干预的方法和组合物
公开(公告)号：US20040219159A1
公开(公告)日：2004-11-04
申请号：US10807963
申请日：2004-03-24
发明人： Graham Stewart , Peadar O'Gaora , Douglas Young
IPC分类号： A61K039/00 , A61K039/38 , A61K039/04
CPC分类号： C07K14/35 , A61K39/04 , A61K2039/52
摘要： Methods and compositions for the treatment and prevention of infectious diseases are provided. In particular, efficient vaccines comprising genetically modified pathogens are provided. The vaccines generally comprise mycobacterial mutants having modified protein production capabilities. In one embodiment, the mutants overexpress heat shock protein. In a specific embodiment, the mycobacterial mutant overexpresses heat shock proteins 60 and/or 70. Also provided are modified BCG vaccines capable of overexpressing heat shock proteins 60 and/or 70.
摘要翻译：提供了治疗和预防感染性疾病的方法和组合物。特别地，提供了包含转基因病原体的高效疫苗。疫苗通常包含具有改变的蛋白质生产能力的分枝杆菌突变体。在一个实施方案中，突变体过表达热休克蛋白。在具体实施方案中，分枝杆菌突变体过表达热休克蛋白60和/或70.还提供能够过表达热休克蛋白60和/或70的经修饰的BCG疫苗。

5. 发明申请

US20040202668A1 Vaccine composition 审中-公开
标题翻译：疫苗组成
公开(公告)号：US20040202668A1
公开(公告)日：2004-10-14
申请号：US10473769
申请日：2004-05-18
发明人： Dominique Boutriau , Carine Capiau , Pierre Michel Desmons , Dominique Lemoine , Jan Poolman
IPC分类号： A61K039/00 , A61K039/38
CPC分类号： A61K39/0018 , A61K39/092 , A61K39/095 , A61K39/102 , A61K39/12 , A61K39/13 , A61K39/29 , A61K39/292 , A61K2039/5252 , A61K2039/55505 , A61K2039/55583 , A61K2039/6037 , A61K2039/70 , C12N2730/10134 , C12N2770/32634 , Y02A50/464 , Y02A50/466 , Y02A50/484
摘要： The present invention relates to new, advantageous DTP-based combination vaccine formulations, and concomitantly administered combination vaccine kits. Methods of administration of these vaccines and kits are also provided.
摘要翻译：本发明涉及新的，有利的基于DTP的组合疫苗制剂和伴随施用的组合疫苗试剂盒。还提供了这些疫苗和试剂盒的给药方法。

6. 发明申请

US20040191267A1 Neisseria spp. polypeptide, nucleic acid sequence and uses thereof 审中-公开
标题翻译：奈瑟氏菌属多肽，核酸序列及其用途
公开(公告)号：US20040191267A1
公开(公告)日：2004-09-30
申请号：US10840530
申请日：2004-05-06
发明人： W. Jackson James , Andrea M. Harris
IPC分类号： A61K039/00 , A61K039/38
CPC分类号： C07K14/22 , A61K38/00 , A61K39/00
摘要： The invention discloses the Neisseria spp. NGSP polypeptide, polypeptides derived therefrom (NGSP-derived polypeptides), nucleotide sequences encoding said polypeptides, and antibodies that specifically bind the NGSP polypeptide and/or NGSP-derived polypeptides. Also disclosed are prophylactic or therapeutic compositions, including antigenic, preferably immunogenic compositions, e.g., vaccines, comprising NGSP polypeptide and/or a NGSP-derived polypeptide or antibodies thereto. The invention additionally discloses methods of inducing an immune response to Neisseria and Neisseria NGSP polypeptide and an NGSP-derived polypeptide in animals.
摘要翻译：本发明公开了奈瑟氏菌属 NGSP多肽，由其衍生的多肽（NGSP衍生的多肽），编码所述多肽的核苷酸序列，以及特异性结合NGSP多肽和/或NGSP衍生多肽的抗体。还公开了预防或治疗组合物，包括抗原性，优选免疫原性组合物，例如包含NGSP多肽和/或NGSP衍生的多肽或其抗体的疫苗。本发明另外公开了在动物体内诱导针对奈瑟球菌和奈瑟氏球菌NGSP多肽和NGSP衍生多肽的免疫应答的方法。

7. 发明申请

US20040191265A1 Stabilized glycoproteins 有权
标题翻译：稳定的糖蛋白
公开(公告)号：US20040191265A1
公开(公告)日：2004-09-30
申请号：US10751744
申请日：2004-01-05
发明人： Mark A. Schenerman , Jose Casas-Finet , Jinhua Feng , Guillermo Tous
IPC分类号： A61K039/00 , A61K039/38
CPC分类号： C07K16/2806 , C07K16/00 , C07K2317/53
摘要： The present invention provides stabilized immunoglobulin molecules that have increased storage stability and/or in vivo half-lives due to the mutation of one or more amino acids that would otherwise render the immunoglobulin molecules susceptible to degradation. In a preferred embodiment, the stabilized immunoglobulins of the invention have mutations at the heavy chain constant domain hinge region. Such stabilized immunoglobulin molecules, i.e., immunoglobulin molecules with increased storage stability have one or more of the following advantages they are more readily transported and/storable for longer periods and/or less stringent conditions than non-stabilized counterparts; that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such stabilized molecules.
摘要翻译：本发明提供了稳定的免疫球蛋白分子，其由于一种或多种氨基酸的突变而具有增加的储存稳定性和/或体内半衰期，否则会导致免疫球蛋白分子易于降解。在优选的实施方案中，本发明的稳定的免疫球蛋白在重链恒定域铰链区具有突变。这种稳定的免疫球蛋白分子，即具有增加的储存稳定性的免疫球蛋白分子具有以下优点中的一个或多个，它们比非稳定的对应物更容易转运和/或更长时间地和/或较不严格的条件运输; 在治疗，预防或诊断使用这种稳定化分子时需要较小的量和或较少频率的给药。

8. 发明申请

US20040180057A1 Neutron capture therapy 审中-公开
标题翻译：中子捕获治疗
公开(公告)号：US20040180057A1
公开(公告)日：2004-09-16
申请号：US10478589
申请日：2004-05-04
申请人： Psimei Pharmaceuticals Ple
发明人： Bipin Chandra Muiibhai Patel
IPC分类号： A61K039/00 , A61K039/38
CPC分类号： C07K16/30 , A61K41/0095 , A61K47/6803 , A61K47/6851 , A61K2039/505 , C07K2317/55
摘要： The present invention relates to immunoconjugates for use in neutron capture therapy, in particular Boron neutron capture therapy, for killing target cells such as tumours. The immunoconjugate of the invention comprises a monoclonal antibody having an affinity of at least 1011 l/mol and a cross-reactivity of less than 10%, and a neutron capture agent. More preferably, the affinity of the monoclonal antibody is at least 1012 l/mol.
摘要翻译：本发明涉及用于中子捕获治疗，特别是硼中子俘获治疗用于杀死靶细胞如肿瘤的免疫缀合物。本发明的免疫偶联物包含具有至少10 11 / mol的亲和力和小于10％的交叉反应性的单克隆抗体和中子捕获剂。更优选地，单克隆抗体的亲和力至少为10 12 l / mol。

9. 发明申请

US20040175389A1 Formulations to increase in vivo survival of probiotic bacteria and extend their shelf-life 有权
标题翻译：制剂增加益生菌的体内存活并延长其保质期
公开(公告)号：US20040175389A1
公开(公告)日：2004-09-09
申请号：US10743402
申请日：2003-12-22
发明人： Randolph Stanley Porubcan
IPC分类号： A61K039/00 , A61K039/38
CPC分类号： A61K35/745 , A61K35/747
摘要： Disclosed is a formulation for preserving the life of probiotic bacteria during passage through the stomach, while permitting their release in the intestine, and which has a low water activity and correspondingly long shelf life. These formulations are designed to retain potency up to the product expiration date. The formulation includes a substantially water-free mixture of probiotic bacteria with monovalent alginate salts, wherein the mixture has been formed and is maintained in a substantially water-free environment. The alginate salts include sodium alginate and potassium alginate, but not divalent salts such as magnesium alginate or calcium alginate. Generally, an enteric coating (e.g., gelatin or cellulose encapsulation) for the formulation is provided.
摘要翻译：公开了一种用于在通过胃中保持益生菌的寿命的制剂，同时允许它们在肠中释放，并且具有低的水活性和相应的长的保质期。这些配方旨在保留效力直到产品到期日。该制剂包括益生菌与单价藻酸盐基本上无水的混合物，其中混合物已经形成并保持在基本上无水的环境中。藻酸盐包括藻酸钠和藻酸钾，但不包括二价盐如藻酸镁或藻酸钙。通常，提供用于制剂的肠溶衣（例如明胶或纤维素包封）。

10. 发明申请

US20040170640A1 Methods for preparing and delivering adjuvant compositions 有权
标题翻译：制备和递送佐剂组合物的方法
公开(公告)号：US20040170640A1
公开(公告)日：2004-09-02
申请号：US10792725
申请日：2004-03-05
发明人： Jay D. Gerber
IPC分类号： A61K039/38 , A61K009/00
CPC分类号： A61K39/39 , A61K39/12 , A61K39/245 , A61K2039/5254 , A61K2039/541 , A61K2039/542 , A61K2039/543 , A61K2039/545 , A61K2039/55511 , A61K2039/55555 , C12N2710/16734
摘要： Methods are provided for preparing and delivering an adjuvant for vaccines including lecithin and a polymer. The polymer is preferably polyacrylic acid-based. The method of preparation includes hydrating lecithin and a polymer in saline or water and mixing the lecithin and polymer to form the adjuvant.
摘要翻译：提供了用于制备和递送包括卵磷脂和聚合物的疫苗佐剂的方法。聚合物优选为基于聚丙烯酸的。制备方法包括将卵磷脂和盐水或水中的聚合物水合并将卵磷脂和聚合物混合以形成佐剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式